Puma Biotechnology has granted inducement restricted stock unit awards covering 7,000 shares of common stock to two new non-executive employees, as approved by its Compensation Committee on June 1, 2026. These awards, part of the company’s 2017 Employment Inducement Incentive Award Plan, will vest over three years. Meanwhile, Puma continues to focus on cancer treatments, with products like NERLYNX® for HER2-positive breast cancer and the development of alisertib for small cell lung cancer and HR-positive metastatic breast cancer.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/press-releases/puma-biotechnology-reports-inducement-awards-under-nasdaq-listing-rule-5635c4-june-3-2026
